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Summary The effects of different doses of hydralazine and prostacyclin on the 31P magnetic resonance spectra
of the LBDS, fibrosarcoma were investigated and related to their effects on mean arterial blood pressure(MABP) and heart rate. The effect of reducing MABP by bleeding the animals, via the tail artery, was also
investigated. Tumour spectral changes following high dose drug treatment (an increase in inorganic phosphate,
a reduction in nucleotide triphosphates and a reduction in pH) were consistent with nutrient deprivation.
These changes were dose dependent. Changes in MABP and heart rate were consistent with vasodilatation in
normal tissues. However, for the same fall in MABP, hydralazine produced a greater rise in tumour inorganic
phosphate (Pi) and a greater fall in tumour pH than did prostacyclin. Controlled bleeding was effective in
reducing MABP. It also reduced tumour pH but had no significant effect on tumour Pi. The clinical
application of the two drugs for reducing tumour blood flow and pH for therapy is likely to be limited by the
large degree of hypotension necessary to produce an effect. The differential effect of the two drugs for the same
fall in MABP may be related to different degrees of direct tumour vasodilatation or to a direct effect of
hydralazine on tumour energy metabolism. The observation that controlled bleeding does not change tumour
Pi is further evidence indicating that the degree of arterial hypotension is not the sole factor in determining
tumour energy status.
Drug-induced reduction in tumour blood flow is potentially
advantageous for some forms of therapy. For instance, Hors-
man et al. (1989) have shown that the arteriolar vasodilator,
hydralazine, can enhance hyperthermic damage in a C3H
mammary carcinoma by decreasing the blood flow to the
tumour. The enhancement was only partially due to more
efficient tumour heating. The extra effect was most probably
brought about by metabolic changes within the tumour and a
decrease in extracellular pH. Although the thermosensitivity
of cells is not changed by chronic adaptation to low pH, for
instance (Hahn & Shiu, 1986), acute metabolic changes and a
decrease in pH are likely to occur following a decrease in
tumour blood flow and these are known to sensitise cells to
heat (Hahn, 1974; Overgaard & Bichel, 1977; Overgaard &
Nielsen, 1980).
Hydralazine has also been shown to potentiate the cytotox-
icity in solid rodent tumours in vivo of the bioreductive drugs
RSU-1069 (Chaplin & Acker, 1987) and SR4233 (Brown,
1987). These drugs are cytotoxic to hypoxic cells and their
potentiation by hydralazine is presumably brought about by
induced hypoxia secondary to a decrease in tumour blood
flow.
Selective reduction of tumour blood flow also has potential
in more conventional chemotherapy. Stratford et al. (1987)
showed that a carefully timed administration of hydralazine
could increase the cytotoxic action of melphalan in trans-
planted rodent tumours whilst normal tissue toxicity
remained unaffected. This could be explained by a hydra-
lazine-induced selective reduction in tumour blood flow
leading to entrapment of melphalan in the tumour tissue.
Hydralazine is used clinically to control hypertension. Its
plasma half-life in man is less than 60 min (Shepherd et al.,
1980), but its half-life in vascular smooth muscle may be as
high as 30 h (Gross, 1977) which is a possible disadvantage
for application in tumour therapy. Horsman et al. (1989)
have shown that, in mice, the mean arterial blood pressure,
which falls on administration of hydralazine, has not return-
ed to normal 8 h after injection. Tumour blood flow was not
measured directly but there was also some indication that it
too had not returned to pre-drug levels by 8 h. Any long-
term reduction in the tumour blood supply would be a
disadvantage for radiotherapy. Therefore, in the present
study, the effect of hydralazine on cardiovascular parameters
and tumour energy metabolism was compared with that of
prostacyclin, an endogenous vasodilator formed from arachi-
donic acid (Moncada et al., 1976). This compound is rapidlyhydrolysed in whole blood and plasma with a half-life of
around 6 min (Orchard & Robinson, 1981). In man, the
onset and offset of the cardiovascular actions of prostacyclin
are rapid, less than 5 min, which means that its effects can be
easily reversed (O'Grady et al., 1980; Lewis & Dollery, 1983).
In order that the potential of hydralazine, prostacyclin and
other vasoactive drugs (for review see Jain & Ward-Hartley,
1984) can be tested clinically, a non-invasive method is
required for measuring changes in tumour oxygen and nutri-
ent status and pH, which are thought to be important for
improving the types of therapy described above. 31P magnetic
resonance spectroscopy (MRS) allows changes in high energy
phosphates, inorganic phosphate and pH of tumours to be
monitored.
The purpose of the present study was to compare the
effects of hydralazine and prostacyclin on the energy meta-
bolism and pH of a transplanted rat fibrosarcoma using 31P
MRS. Vasodilatation in normal tissues, with a consequent
decrease in arterial blood pressure, would lead to a decrease
in tumour blood flow, from the relationship
blood flow through a tissue =
arteriovenous pressure difference + vascular resistance
A direct vasodilatory effect on tumour blood vessels would
reduce tumour vascular resistance and tend to counteract this
effect. In order to determine the role of a reduction in mean
arterial blood pressure in drug effects on tumour energy
metabolism, this parameter was measured simultaneously
with 31P MRS. Other cardiovascular parameters were
measured on a separate group of animals.
Materials and methods
Tumours
A transplanted rat fibrosarcoma, designated LBDS,, was
used for these experiments. Details of the origin of this
tumour and its maintenance have been described elsewhere
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(Tozer & Morris, 1990). Briefly, maintenance involves sub-
cutaneous transplantation of 1-2 mm3 tumour pieces into the
right flanks of 8-12-week-old male BD9 rats. Only tumours
between the 7th and 14th generation away from the spon-
taneous tumour were used for these experiments.
Rats were used for experiments when their tumours reach-
ed a mean diameter of between 14 and 16 mm (including skin
thickness). This took approximately 1 month from the time
of transplantation.
Administration of drugs and measurement of cardiovascular
parameters
Tumour-bearing rats were anaesthetised with fentanyl citrate
(0.315 mg kg-') and fluanisone (10mg kg-') ('Hypnorm',
Crown Chemical Co. Ltd) and midazolam (5 mg kg-')
('Hypnovel', Roche). This anaesthetic mixture will subse-
quently be referred to as Hypnorm and midazolam. Poly-
ethylene catheters, internal diameter 0.58 mm and external
diameter 0.96 mm, containing heparinised 0.9% saline were
implanted into a tail vein and a tail artery. The tail artery
catheter was connected to a Gould P23XL physiological
pressure transducer via a sufficient length of pressure tubing,
such that MABP of the rat could be recorded with the rat in
the bore of the magnet. Rectal temperature was maintained
at 37°C during the operating procedure by the use of a
thermostatically controlled heating pad.
Vasoactive drugs were administered via the tail vein
catheter without disturbing the position of the rat in the bore
of the magnet. Hydralazine (Sigma) was dissolved in steril-
ised water and administered as a bolus at doses between
0.1 mg kg-' and 1.0 mg kg-' in a volume of 0.8 ml kg-'.
Prostacyclin (Wellcome) is unstable at physiological pH. It
was made up in 1.5% w/v NaHCO3 at pH 9.5 and admin-
istered as a constant infusion at a rate of 0.045 ml min-' and
at doses between 10 ng kg-' min-' and 360 ng kg-' min-' for
60 min. Control animals were infused with 1.5% w/v
NaHCO3 at a constant rate of 0.045 ml min-' for 60 min.
A polyethylene catheter was also implanted i.p. for 'top-
up' doses of anaesthetic whilst the rat was in the magnet.
Hypnorm and midazolam were administered at one-sixth the
induction dose every 45 min during collection of spectra.
These extra doses produced no consistent changes in MABP.
The MABP of one group of animals was reduced by
controlled bleeding via the tail artery catheter, whilst the rats
were positioned in the magnet. These animals received no
vaso-active drug treatment.
Preliminary experiments were performed to determine the
doses of hydralazine and prostacyclin which produced an
iso-effect in terms of reduction in MABP. Two iso-effect
doses were chosen. The 'high' iso-effect doses for the two
drugs produced an initial reduction in MABP, during the
first 20min following the start of drug administration, to
approximately 55mmHg, and the 'low' doses an initial
reduction to approximately 70mmHg. The high dose was
1 mg kg-' for hydralazine and 160 ng kg-' min-' for prosta-
cyclin. The low dose was 0.1 mg kg-' for hydralazine and
10 ng kg- 'min-' for prostacyclin. These doses were used to
compare the effects of the two drugs on tumour 31P spectra
for the same fall in MABP. A higher dose of prostacyclin
(360 ng kg-l min-') was also used to determine the effects of
hypotention below 50mmHg on tumour 31p spectra. Other
doses were used to obtain dose-response curves for the two
drugs.
The effects of 1 mg kg-' hydralazine and 160 ng kg-'
min-' prostacyclin on MABP, systolic blood pressure, dia-
stolic blood pressure, pulse pressure and heart rate were
measured on separate groups of tumour-bearing catheterised
animals using a physiological pressure transducer connected
to a Gould RS3200 recorder.
31P magnetic resonance spectroscopy
31P MRS studies were carried out at 1.89T on an Oxford
Research Systems TMR-32 spectrometer. Anaesthetised,
catheterised rats were placed on two plastic tissue culture
flasks containing recirculating warm water. The rats were
positioned on their sides such that the flank tumour hung
vertically downwards between the flasks and rested gently on
a 20mm diameter, two-turn surface coil. This set-up was
located within the horizontal bore of the magnet and
minimised the risk of contamination of the tumour spectra
by phosphates from underlying and adjacent normal tissue.
31P data were obtained in blocks of 10 or 20 min (from the
sum of 300 or 600 free induction decays, respectively) with a
pulse length of 10 gis and a pulse repetition time of 2 s. The
resulting spectra therefore represented levels of phosphate
metabolites averaged over the scanning period. The time for
each scan was taken as the mid-point of each scanning
period. The 900 pulse at the centre of this surface coil was
7 ,is. Data processing involved exponential weighting (equiva-
lent to 15 Hz line broadening) and spectral deconvolution (to
remove broad spectral lines) as described previously (Tozer et
al., 1989). Peak integration was performed by a computer
programme which allowed operator definition of the baseline
and peak limits.
Tumour pH (pHMRS) was evaluated from the chemical shift
of the inorganic phosphate peak from the phosphocreatine
peak using the calibration of Pritchard et al. (1983).
Results
Figure 1 shows examples of tumour 31P spectra obtained
before and 5-25 min after bolus administration and the start
of constant infusion of hydralazine and prostacycin respec-
tively. Qualitative changes in the spectra following treatment
are the same for the two drugs. The most significant changes
are an increase in the inorganic phosphate (Pi) peak and a
decrease in the nucleotide triphosphate (NTP) peaks. The
phosphocreatine peak also tends to decrease. These changes
are consistent with drug-induced nutrient deprivation of the
tumours.
Since drugs were administered without disturbance of the
animals' position within the magnet, it was possible to inves-
tigate changes of individual peak areas after drug administra-
tion. Peak areas were compared with their pre-drug levels
using the Student's t test for paired data. Figure 2 shows
changes in peak areas for inorganic phosphate (Pi), P-nucleo-
tide triphosphate (P-NTP), phosphocreatine (PCr), phospho-
monoesters (PME) and phosphodiesters (PDE) for a group
of animals treated with hydralazine 1 mg kg-' (Figure 2a)
and a group treated with prostacyclin 160ngkg-'min-'
(Figure 2b).
The peak area for Pi was doubled following injection of
hydralazine. It remained elevated for the duration of the
experiment (P<0.05), but with a gradual decline after the
first 30 min post-drug towards control values. The P-NTP
peak area decreased significantly after injection of hydra-
lazine (P<0.05). There was some subsequent recovery but,
at the end of the experiment P-NTP was still significantly
below the pre-drug level (P = 0.04). PCr was significantly
reduced in the first scan following injection (P = 0.02), but
was not significantly reduced thereafter. Apparent changes in
PME and PDE did not reach statistical significance with the
animal numbers used.
The peak area for Pi was also significantly increased dur-
ing the start of infusion of prostacyclin (P <0.05 for the first
two scans after the start of infusion) (Figure 2b). However,
this increase was not as large as for hydralazine and
decreased back towards control values during the 60 min
infusion. Changes in the other phosphates were more vari-
able than for the hydralazine-treated animals. P-NTP was
significantly reduced at the start of infusion (P = 0.01) but
had returned to control values by the end. There were no
very convincing changes in PCr, PME or PDE. Only the
decrease in PDE during the first scan following start of
infusion was statistically significant (P = 0.03). After stopp-
ing the infusion there was some indication of an increase in
NTP and PCr above control levels, but these did not reach
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Figure 1 31P spectra from LBDS, tumours. The spectra were obtained from one animal (a) before and (b) 5-25 min after the start
of prostacyclin infusion (160ngkg-'min-') and from a second animal (c) before and (d) 5-25 min after a bolus injection of
hydralazine (I mg kg-'). Peak assignments as indicated in (b) are as follows: phosphomonoesters (PME), inorganic phosphate (Pi),
phosphodiesters (PDE), phosphocreatine (PCr) and P-nucleotide triphosphate (P-NTP).
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Figure 2 The effect of hydralazine (1 mg kg-') (a) and prosta-
cyclin (160 ng kg-' min-') (b) on the peak spectral areas for Pi,
NTP, PCr, PME, PDE for the LBDS, tumour. Values are means
± I s.e.m. Times are the mid-points of spectral collection except
that time 0 is the end of the first collection. Arrows in (b)
represent the start and stop of prostacyclin infusion. n = 4 for
hydralazine and n = 7 for prostacyclin. -0- Pi, A- NTP,
-. A - PCr, -U- PME, -- 0 -- PDE.
statistical significance (P = 0.06 and 0.07 respectively) and
had returned to control levels during the second 20 min scan
post-infusion.
From Figure 2, the changes in Pi tend to be mirrored by
changes in P-NTP. The Pi changes are the largest changes in
the tumour 31p spectra following administration of hydra-
lazine and prostacyclin. This is presumably because Pi is the
end-product in the breakdown of all high energy phosphates.
Pi has therefore been used as an index of tumour nutrient
status in the following analyses. Another possible explanation
for the large changes in Pi following drug treatment is that Pi
is appearing from an 'MRS-invisible' pool such as an im-
mobile phosphate species. However, the total amount of 31p
metabolites visible by MRS did not significantly change
following drug treatment (results not shown) suggesting that
this was not the case.
Figure 3 shows the dose response of changes in Pi peak
area following administration of hydralazine (Figure 3a) and
prostacyclin (Figure 3b). The lowest dose of hydralazine
(0.1 mg kg-') and prostacyclin (10 ng kg-' min-) had no
significant effect on tumour spectra. Higher doses of each
drug produced a dose-dependent increase in Pi up to the
highest doses used. The pattern of change in Pi was similar,
for all effective doses, to those observed for the doses studied
in Figure 2. Hydralazine tended to cause an increase in Pi
with a gradual reduction towards control levels at later times.
Pi had returned to control levels by 220 min post-injection
for 0.4 mg kg-' hydralazine (P = 0.53, Student's t test for
paired data). This was not the case for 1.0 mg kg-' hydra-
lazine where all values of Pi were above control levels
(P<0.01). Prostacyclin caused an initial increase in Pi but
with a rapid return towards control levels throughout the
60 min infusion. Pi returned to control levels after stopping
the infusion.
Figure 4a shows the effects of 1 mg kg-' hydralazine and
Figure 4b of 160 ng kg- min' l prostacyclin on MABP and
heart rate. Both drugs caused a significant decrease in MABP
and increase in heart rate. Changes in MABP were dose-
dependent (results not shown). The initial fall in MABP was
rapid for both drugs but there was some recovery over the
60 min infusion period for prostacyclin. This may be due to
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Figure 3 Dose response for hydralazine (a) and prostacyclin (b)
on the peak spectral area for Pi for the LBDS, tumour. The
numbers on the lines are the doses for hydralazine in mgkg-'
and prostacyclin in ng kg-' min- Values are means ± I s.e.m.
for 3-10 animals. Times are the mid-points of spectral collection
except that time 0 is the end of the first collection. The arrow in a
is the time for injection of hydralazine. Arrows in b represent the
start and stop of prostacyclin infusion.
reflex catecholamine release. MABP following hydralazine
remained depressed throughout the 2.5 h of the experiment.
A greater reduction of systolic blood pressure than diastolic
blood pressure was observed for both drugs, resulting in a
reduction of the pulse pressure by an average of 13 mmHg
for hydralazine and 8 mmHg for prostacyclin. In conscious
man (O'Grady et al., 1980) the reverse is true for prostacyclin
where diastolic blood pressure was affected more than systol-
ic blood pressure, in keeping with the vasodilatory properties
of the drug. In the rat, general anaesthesia may have affected
the relationship between systolic and diastolic blood pressure.
In mice it has been shown that hydralazine affects diastolic
blood pressure more than systolic if the animals are cons-
cious but the reverse is true if the animals are anaesthetised
with Hypnorm and midazolam (I. Ali-Burney, personal com-
munication).
Tachycardia, induced by hydralazine, as shown in Figure
4a, is a well known sympathetic reflex response to the hypo-
tension induced by this drug (Gross, 1977). Prostacyclin,
depending on the doses used and the basal heart rate, has
been shown to induce both tachycardia, as a result of stimu-
lation of baroreceptor reflexes, and bradycardia, due to
stimulation of a vagal reflex (Chiavarelli et al., 1982). In the
present experiments, 160 ng kg-' min' prostacyclin was
found to induce tachycardia (Figure 4b). The two drugs
increased heart rate by a similar amount (approximately 60
beats minm) suggesting an increase in the cardiac output.
Armstrong et al. have found an increase in the cardiac
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Figure 4 The effect of hydralazine (1 mg kg-') (a) and prosta-
cyclin (160ngkg-'min-') (b), on MABP and heart rate in the
BD9 rat. Values are means ± 1 s.e.m. Arrows in b represent the
start and stop of prostacyclin infusion. n = 5 for hydralazine and
n = 5 for prostacyclin.
output of dogs during infusion of prostacyclin (Armstrong et
al., 1977).
Figure 5 shows the results for animals in which MABP was
measured and tumour 31P spectra were collected simultan-
eously. One value for MABP was calculated over each
20 min scan period by averaging the MABPs read from the
chart recording every minute. These values are plotted
together with % change in Pi in Figure 5 for each spectrum
collected over a total time of approximately 2 h. Time zero
represents the time of bolus injection of hydralazine and
start of infusion of prostacyclin. Prostacyclin infusion was
stopped at 60 min. Figure 5a is for the high iso-effect doses
of hydralazine and prostacyclin (1 mg kg-' and 160 ng kg-'
min-' respectively). The mean reduction in MABP, between
0 and 60 min was very similar for the two drugs in this group
of animals (dashed lines in Figue Sa). However, hydralazine
is much more effective than prostacyclin in increasing Pi at
these doses (continuous lines in Figure Sa). The difference in
Pi during the first scan post-drug for the two drugs does not
quite reach statistical significance at the 5% level (P = 0.06,
Student's t test for unpaired data). The difference in MABP
is also not significant (P = 0.90). However, %Pi for hydra-
lazine is significantly higher than for prostacyclin for the
second and third scans post-drug (P = 0.002 and 0.001
respectively) despite no significant difference in MABP for
the two treatment groups at these times (P = 0.06 and 0.11
respectively). During the fourth and fifth scans post-drug,
%Pi is still significantly higher for hydralazine than for
prostacyclin (P<0.001 for both scans), but the difference in
MABP for the two treatment groups also becomes significant
at these times (P = 0.01 for both scans).
Figure Sb shows results for the low iso-effect doses of
hydralazine and prostacyclin (0.1 mg kg-' and 10 ng kg-'
min-' respectively). In this case, the two drugs had no
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Figure 6 The effect of changes in mean arterial blood pressure
(MABP) induced by 1.0 mg kg-' hydralazine (filled circles, n =
4), 160 ng kg-' min-' prostacyclin (open squares, n = 7) and
360 ng kg-' min-' prostacyclin (dotted squares, n = 6) on tumour
Pi expressed as a % of control values. Each point represents data
from a group of animals within a treatment group at different
times following administration of drug. Values are means +
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Figure 5 The effect of high dose hydralazine (1 mg kg-') and
prostacyclin (160ngkg-'min-') (a) and low dose hydralazine
(0.1 mg kg-') and prostacyclin (10 ng kg- ' min ') (b) on the peak
spectral areas for Pi for the LBDS, tumour and on the MABP of
the host rats. Continuous lines represent Pi levels and broken
lines represent MABP as shown in a. Filled symbols represent
hydralazine and open symbols represent prostacyclin. Values are
means ± 1 s.e.m. for 4 rats for hydralazine and 7 rats for prosta-
cyclin in a and 3 rats for hydralazine and prostacyclin in b. Times
are mid-points of spectral collections except that time 0 is the end
of the first collection. Filled arrows represent time for injection of
hydralazine and start of infusion of prostacyclin. Open arrows
represent the time of stopping prostacyclin infusion.
significant effect on tumour Pi (solid lines) (P> 0.05 for each
value of Pi compared to its pretreatment level, using the
Students' t test for paired data) despite a significant reduc-
tion in MABP (dashed lines).
Figure 6 shows, more directly, the relationship between
MABP and Pi for the two drugs. A single dose of hydra-
lazine is compared with two doses of prostacyclin. Data for
mg kg' hydralazine and 160 ng kg' min-' prostacyclin
are the same as in Figure 5a. Pi only begins to rise when
MABP is reduced to below about 65 mmHg. As MABP
decreases below 65 mmHg, hydralazine causes a steep in-
crease in Pi. Prostacyclin causes less of an effect on Pi than
hydralazine for the same reduction in MABP and reduction
of MABP below about 55 mmHg appears to cause no further
increase in Pi for this drug.
Figure 7 shows the results for the group of animals in
which systemic blood pressure was reduced by controlled
bleeding via the tail artery catheter. Measurement of MABP
and collection of tumour spectra were carried out simul-
taneously as described previously. MABP was reduced in
stages over a 2 h period down to approximately 45 mmHg
(dashed line in Figue 7). This reduction did not have a
significant effect on tumour Pi levels (continuous line in
Figure 7) (P> 0.05 for each value of Pi compared to its
pretreatment level, using the Student's t test for paired data).
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Figure 7 The effect of controlled bleeding on the peak spectral
areas for Pi for the LBDS, tumour and on the MABP for the
host rats. Values are means± I s.e.m. for 4 rats. Times are the
mid-points of spectral collections except that time 0 is the end of
the first collection. The arrow represents the start of withdrawal
of blood.
Tumour pH (pHMRS) was calculated for most of the spec-
tra collected. However, sometimes this was not possible due
to poor resolution of the PCr or Pi peaks. Figure 8a shows
the change in tumour pH for high dose administration of
hydralazine (1 mg kg-') and prostacyclin (160 ng kg-'
min-'). The reduction in pH induced by hydralazine was
significant (P<0.05 for each value of pH compared with its
pretreatment level, using the Students' t test for paired data)
up to 72 min post-injection. The reduction induced by prosta-
cyclin was less than that induced by hydralazine but was
still significant throughout the 60 min infusion (P<0.05). It
had returned to pre-treatment values after stopping the
infusion.
Figure 8b shows the change in tumour pH for low dose
administration of hydralazine (0.1 mg kg-') and prostacyclin
(10 ng kg-' min'1). Tumour pH was significantly reduced
from pre-drug levels at 30 min post-injection of hydralazine
(P = 0.015, Student's t test for paired data) but there were no
consistent changes with time and pH at the other time points
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Figure 8 The effect of hydralazine and prostacyclin administra-
tion and controlled bleeding on LBDS, tumour pH. a is for high
drug doses (1 mg kg-' hydralazine, 160 ng kg- min-' prostacyc-
lin). b is for low drug doses (0.1 mg kg-' hydralazine and 1O ng
kg- min-' prostacyclin). c is for controlled bleeding. Times are
the mid-points of spectral collections except that time 0 is the end
of the first collection. Filled arrows in a and b represent the time
of injection of hydralazine and the start of prostacyclin infusion.
The arrow in c represents the start of withdrawal of blood.
Values are means ± I s.e.m., n is the number of animals.
was not significantly different from pre-drug pH. Low dose
prostacyclin had no significant effect on tumour pH during
infusion. The reason for the fall in pH in this group of
animals, after stopping the infusion, is not known.
The effect of controlled bleeding on tumour pH is shown
in Figure 8c. Tumour pH was reduced significantly for the
later time points (>40min) at which MABP was severely
reduced (see Figure 7). The reduction was very similar to that
induced by 1 mg kg-' hydralazine for which there was also a
comparable reduction in MABP.
The relationship between MABP and tumour Pi and-pH is
complicated. Summarising the results:
1. High dose hydralazine (1 mg kg-') and high dose pro-
stacyclin (160 ng kg-' min-' and 320 ng kg-' min-') caused
substantial falls in MABP. Although the kinetics were
different, both drugs were effective in increasing tumour Pi
levels and reducing tumour pH.
2. Low dose hydralazine (0.1 mg kg-') and low dose
prostacyclin (10 ng kg- min-') had no significant effect on
tumour Pi levels and tumour pH despite a significant reduc-
tion in MABP for both drugs.
3. Hydralazine was more effective than prostacyclin in
increasing tumour Pi levels and reducing tumour pH for the
same initial fall in MABP.
4. Reduction in MABP by controlled bleeding was as
effective as hydralazine (1 mg kg-1) in reducing tumour pH.
However, there was no increase in tumour Pi when MABP
was reduced by this method.
Discussion
We have previously shown (Tozer et al., 1989) that the
energy metabolism of transplanted rodent tumours is affected
by their growth and by treatment with X-rays. These changes
are most likely brought about by alterations in tumour blood
flow.
Recent studies have shown that i.p. or i.v. administration
of hydralazine to mice can decrease PCr, NTP and pH, and
increase Pi in several murine tumours growing in different
sites (Okunieff et al., 1988; Dunn et al., 1989). Our results are
broadly in agreement with these findings. The spectral
changes brought about by high dose treatment with hydra-
lazine or prostacyclin are most likely to be largely due to
changes in tumour blood flow. A reduction in tumour blood
flow has been demonstrated in dogs and in rodents following
administration of hydralazine (Voorhees & Babbs, 1982;
Horsman et al., 1989). A hydralazine-induced increase in
blood flow to normal tissues, without a reduction in tumour
blood flow itself, has also been demonstrated, causing a
reduction in the ratio of tumour to normal tissue blood flow
(Babbs et al., 1982; Chan et al., 1984). The effect of prosta-
cyclin on tumour blood flow has not been studied.
In the present study, tachycardia, following administration
of hydralazine and prostacyclin, suggests an increase in car-
diac output in an attempt to compensate for the hypotension
(cardiac output =heart rate x stroke volume). Vasoactive
agents can modify tumour blood flow directly via changes in
tumour vascular resistance or indirectly via changes in blood
pressure (blood flow through a tissue = arteriovenous pres-
sure difference -. vascular resistance). The direct effect is
likely to be less than that in normal tissues because tumour
blood vessels are generally less well endowed with vascular
smooth muscle than normal tissue blood vessels (Warren,
1979). Therefore, any potential drug-induced increase in
tumour blood flow resulting from vasodilation of tumour
blood vessels and a decrease in vascular resistance was prob-
ably masked, in the present experiments, by the hypotensive
effect of the two drugs at all doses used. Where there are
minimal effects on MABP it is possible to demonstrate an
increase in PCr/Pi of animal tumours (Okunieff et al., 1988).
At very high doses of the drugs, it is possible that the
reduction in tumour blood flow brought about by hypoten-
sion is compounded by vascular collapse resulting from a
reduction in intravascular pressure to below that of the
interstitial pressure (Jain, 1988). This is more likely to occur
in tumours than in normal tissues because of their high
interstitial pressure (Wiig et al., 1982).
Horsman et al. (1989) showed that the radiobiologically
hypoxic fraction of a C3H mouse mammary tumour in-
creased and its blood flow decreased following administration
of hydralazine. Hypoxia, in the rat fibrosarcoma, resulting
from a decrease in tumour blood flow would be expected to
cause the observed increase in Pi, decrease in NTP and
decrease in PCr of this tumour via the enzyme reactions
catalysed by adenylate kinase and creatine kinase. Tumour
pH would also be expected to decrease, in the initial stages
before depletion of glucose, as a result of an increase in
anaerobic glycolysis.
A large reduction in MABP was necessary, for both hydra-
lazine and prostacyclin administration, before any effects on
tumour spectra were observed. 'Low dose' hydralazine and
prostacyclin caused MABP to fall to approximately
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70 mmHg without affecting Pi or pH. 'High dose' drug treat-
ment which produced significant changes in Pi and pH corre-
sponded to a fall in MABP to approximately 55 mmHg.
Significant spectral changes were also observed by Okunieff
et al. (1988) only when MABP was reduced to around
60 mmHg. Such a reduction in MABP is not feasible clini-
cally. Furthermore, the hypotensive effects of hydralazine
and prostacyclin in the rat experiments were compounded by
the hypotensive effect of general anaesthesia. Equivalent,
weight-adjusted drug doses in conscious man would not be
expected to be so effective, even if such severe hypotension
were feasible. The maximum well-tolerated dose in conscious
man for prostacyclin is around 8 mg kg-' min-'. This pro-
duces a fall in MABP of approximately 15 mmHg and an
increase in heart rate of about 20 beats min-' (Lewis &
Dollery, 1983).
The whole question of artefacts introduced into spectral
measurements by the use of general anaesthesia is an impor-
tant one. Unfortunately, we have not found a satisfactory
method for sufficiently restraining conscious rats for 31P
MRS without causing the animals considerable stress. How-
ever, the fact that the results of Okunieff et al. (1988), for
hydralazine administration to conscious mice, are similar to
ours, suggests that anaesthesia is not qualitatively affecting
the results.
Despite the reservations regarding effective doses, it is still
possible that drugs such as hydralazine and prostacyclin may be
clinically useful. Firstly, the sensitivity of changes in energy
metabolism, as a marker for changes in tumour blood flow, is
not known. Therefore, it is possible that a moderate reduction in
tumour blood flow may occur for a moderate fall in MABP.
This is suggested by the work of Vaupel (1975). Secondly, an
increase in blood flow to the normal tissue surrounding the
tumour may occur at moderate reductions in MABP for which
tumour blood flow is unchanged. Either of these possibilities
would facilitate, for instance, tumour heating for hyperthermia
treatments. This would be beneficial, even in the absence of
increased thermal sensitivity gained from nutrient deprivation
of the tumour itself.
The potential advantage of the short biological half-life of
prostacyclin compared with that of hydralazine was outweighed
by its apparent reduced effect on spectral parameters for the
same initial reduction in MABP. The reason for this differential
effect is unclear. Hydralazine acts directly on the vascular
smooth muscle of arterioles for its vasodilatory effect although
its exact mechanism of action is unknown. Vasodilatation by
prostacyclin results from its stimulation of adenylate cyclase
which raises intracellular levels of cyclic adenosine monophos-
phate (Weksler, 1984; Hopkins & Gorman, 1981). This general
effect is likely to result in dilatation of al! :ypes of blood vessels
endowed with smooth muscle.
The net affect of vasodilator on tumour blood flow will be
dependent on a balance between its indirect effects arising from
hypotension caused by vasodilatation in normal tissues and
direct effects arising from dilatation of the tumour blood vessels
themselves. It is therefore possible that prostacyclin has a
greater direct dilatory effect on tumour blood vessels than
hydralazine. This would tend to counteract the indirect effect of
a fall in MABP and maintain blood flow through the tumour.
The possibility of direct dilatation of tumour blood vessels
depends on (1) their smooth muscle investment, (2) their
vascular tone and (3) possession of the relevant receptors.
Tumour blood vessels are generally rather poorly endowed with
vascular smooth muscle (for review of tumour vascular mor-
phology see Warren (1979)). However, normal blood vessels
may be incorporated into the tumour mass during its growth
and this will depend upon tumour type (Falk, 1977). Smooth
muscle investment also depends upon the size of blood vessels.
Falk (1977) found that, for one particular type offibrosarcoma,
both veins and arteries retained a muscular investment until the
branching became very fine. Receptor analyses oftumour blood
vessels have not been carried out. The balance between indirect
and direct effects ofvasoactive agents on tumour blood flow has
been discussed by Jirtle (1988). The possibility of direct
dilatation or constriction of tumour blood vessels requires
specific investigation before the therapeutic potential of vaso-
active agents can be properly exploited.
Other characteristics of the two drugs could produce a
differential effect on tumour blood flow. Prostacyclin is anti-
aggregatory for platelets (Pace-Asciak & Gryglewski, 1983).
This may be important if platelet aggregation in tumours is
significant. Vasodilatation in the normal tissues surrounding the
tuniour may also be different for the two drugs for the same level
of hypotension. We are currently investigating whether the
differential effect of hydralazine and prostacyclin in tumour
energy metabolism is reflected by a similar differential effect on
tumour blood flow.
A direct biochemical effect of hydralazine could also play a
role in its effect on tumour energy metabolism. It is known that
hydralazine inhibits the action of various enzymes and this may
be associated with its ability to chelate metal ions such as Fe2 ,
Fe3` and Cu2+ (Gross, 1977). Hydralazine is metabolised in the
body by acetylation via acetyl coenzyme a which is an ATP
requiring process (Douglass et al., 1957). It is also known
(Gross, 1977) that sublethal doses of hydralazine can reduce
levels ofhigh energy phosphates in the brain and depress oxygen
uptake in preparations of brain, liver and kidney of rats.
Depite the relationship demonstrated between drug-induced
systemic hypotension and tumour Pi (Figure 6), systemic
hypotension is not, on its own, a good indication of changes in
the tumour micro-environment. This is illustrated by the
spectral changes observed for rats whose MABP was reduced by
controlled bleeding. Reduction of MABP to levels comparable
with those induced by hydralazine was obtained by this method.
However, although tumour pH was also reduced comparably,
tumour Pi remained unchanged. This result is difficult to
explain. Vaupel (1975) has investigated the effect of controlled
bleeding on MABP and blood flow in the DS-carcino-sarcoma
implanted into rat kidneys. He showed that blood flow was
linearly related to MABP within the range of40- 135 mmHg. If
this is the case for the subcutaneous fibrosarcoma in the current
experiments then one would expect Pi to be significantly
affected. Catecholamine release, due to blood loss, would tend
to increase glycolysis and this may be sufficient to maintain high
energy phosphate levels under these conditions. An increase in
lactate levels would then explain the decrease in pH. Another
possiblity is that venous pressure will be reduced following
controlled bleeding and this may, in turn, reduce tumour
interstitial pressure. Such a reduction could maintain tumour
blood flow despite a fall in arterial blood pressure. Obviously the
relationship between MABP, tumour phosphate levels and
tumour pH is very complicated and requires further investiga-
tion.
In conclusion, 31P MRS was useful for monitoring the effects
of vasoactive drugs on tumour energy metabolism. Vasoactive
drugs such as hydralazine and prostacyclin, which appear to
affect tumour energy metabolism primarily via their vaso-
dilatory effects on normal tissues, which reduces systemic blood
pressure, may be ineffective in altering tumour energy meta-
bolism clinically because of the severe systemic hypotension
involved. The differential between the effects of hydralazine,
prostacyclin and controlled bleeding on tumour energy meta-
bolism, for the same degree of systemic hypotension, suggests
further studies on the direct versus indirect effects ofhydralazine
on tumour energy metabolism. This would be desirable for a
systematic approach to finding methods for manipulating
tumour blood flow for optimisation of therapy.
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